Defeating cancer starts with early detection
Today, the majority of cancers are found too late, when the prognosis is often poor and treatment options are limited.1 The earlier that cancer is diagnosed, the greater the chance of successful treatment and survival.2
5‑year mortality rate2,3
Increase the chances of early cancer detection
The Galleri® test is a multi-cancer early detection test that detects methylation patterns of cell-free DNA (cfDNA) that could indicate the presence of cancer. When a cancer signal is detected, the test predicts the origin of the cancer signal with high accuracy. The Galleri test should be used in addition to guideline-recommended cancer screenings and is recommended for patients at elevated risk for cancer such as those aged 50 or older.
Sign up for more information about the Galleri test
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7 – 33.
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50 – 79 diagnosed 2006 – 2015.“Early/Localized” includes invasive localized tumors that have not spread beyond organ of origin.“Late/Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.
Noone AM, Howlader N, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975 – 2015, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER website April 2018.
Screening includes methods recommended by United States Preventive Services Task Force (USPSTF) A and B ratings.
Among individuals 50 – 79 years old. Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 33% of lung cancer cases (based on estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years).
Data on file from Surveillance, Epidemiology, and End Results (SEER) 18 Regs Research Data, Nov 2017 Submission. Includes persons aged 50 – 79. Estimated deaths per year in 2020 from American Cancer Society Cancer Facts and Figures 2020. Available at: www.cancer.org/content/dam/cancer— org/research/cancer— facts— and— statistics/annual— cancer— facts— and— figures/2020/cancer— facts— and— figures— 2020.pdf
Klein E, et al. Clinical validation of a targeted methylation·based multi-cancer early detection test. Oral presentation at: American Association for Cancer Research; April, 2021; LB013.
Based on Surveillance, Epidemiology, and End Results (SEER) incidence in individuals 50 – 79 years old who are screening eligible and have average risk of cancer. Data on file. Assumes nationally-representative adherence to USPSTF A, B, or C recommended screening (breast, colorectal, lung, cervical, and prostate cancer) and 100% screening with MCED test in the USPSTF-screened group. Baseline population of 107M (men and women aged 50 — 79; US Census Bureau. Annual Estimates of the Resident Population by Single Year of Age and Sex for the United States. https://www.census.gov/data/tables/time— series/demo/popest/2010s— national— detail.html. Accessed 5/29/20.).